Study on BMS-986449 With and Without Nivolumab for Advanced Solid Tumors

Sponsor: Bristol-Myers Squibb

Sponsor score: 60
Inactive

ClinicalTrials ID:NCT05888831

Provider View

This clinical trial is testing the safety and effectiveness of a new drug, BMS-986449, both alone and in combination with another drug, nivolumab, in patients with advanced solid tumors.

Patient Parameters

Program Overview

The aim of this study is to find out if the new drug BMS-986449, used by itself or together with nivolumab, is safe and can help treat people with advanced solid tumors that cannot be surgically removed or have spread to other parts of the body.

Eligibility Criteria

Inclusion Criteria

  • Have a confirmed diagnosis of advanced solid cancer that cannot be surgically removed or has spread, and have tried all other treatments that are known to help.
  • For Part 1A, any type of solid cancer is allowed.
  • For Part 1B, only patients with non-small cell lung cancer (NSCLC) can participate.
  • For Part 1C, only patients with triple-negative breast cancer (TNBC) can participate.
  • Must be able to provide a tumor biopsy unless it is not medically possible.

Exclusion Criteria

  • Have had severe side effects (Grade 3 or higher) from previous treatments that target the immune system, unless these side effects are not expected to happen again with standard treatments.
  • Have had recent gastrointestinal issues or surgery that could affect how the body absorbs the study drug.
  • Have any serious medical condition that could interfere with the study treatment or follow-up, according to the study doctor.
  • Other specific criteria may apply as defined in the study protocol.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.